Top of this page
Skip navigation, go straight to the content
Welcome to UCB Investor Relations
Our Investor Relations team aim to serve analysts, shareholders and potential investors with timely, valuable and reliable information.
UCB has the potential to become the next generation biopharma leader
- Powerful and unique combination of biology and chemistry research capabilities
- A track record of turning novel ideas into therapeutic and commercial realities
- Solid product life-cycle management
Lorem
More information
Quick access
News List ›
- UCB accelerates transition to become patient-centric global biopharmaceutical leader with decision to exit the primary care market in the U.S. 29-Jan-2010
- UCB announces initial clinical trial results involving patients taking certolizumab pegol for moderate to severe Crohn?s disease 21-Dec-2009
- UCB signs a new EUR 1.5 billion credit facility 15-Dec-2009
- UCB completes the placement of 7-year bonds 03-Dec-2009
